Role of the Adjacent Stroma Cells in Prostate Cancer Development and Progression: Synergy between TGF-\(\beta\) and IGF Signaling

Chung Lee,1,2,3,4 Zhenyu Jia,3,5,6 Farah Rahmatpanah,3 Qiang Zhang,1 Xiaolin Zi,2 Michael McClelland,3 and Dan Mercola3

1 Department of Urology, Northwestern University Feinberg School of Medicine, Tarry Building, Room 16-733, 303 East Chicago Avenue, Chicago, IL 60611, USA
2 Department of Urology, University of California at Irvine, Medical Center, Orange, CA 92868, USA
3 Department of Pathology and Laboratory Medicine, University of California at Irvine, Medical Surgery Building I, Room 168, Irvine, CA 92697, USA
4 Department of Surgery, NorthShore University HealthSystem, Evanston, IL 60201, USA
5 Department of Statistics, University of Akron, Akron, OH 44325, USA
6 Department of Family and Community Medicine, Northeast Ohio Medical University, Rootstown, OH 44272, USA

Correspondence should be addressed to Chung Lee; c-lee7@northwestern.edu

Received 29 January 2014; Accepted 28 May 2014; Published 25 June 2014

Academic Editor: Leland Chung

Copyright © 2014 Chung Lee et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

This review postulates the role of transforming growth factor-beta (TGF-\(\beta\)) and insulin-like growth factor (IGF-I and IGF-II) signaling in stromal cells during prostate carcinogenesis and progression. It is known that stromal cells have a reciprocal relationship to the adjacent epithelial cells in the maintenance of structural and functional integrity of the prostate. An interaction between TGF-\(\beta\) and IGF signaling occupies a central part in this stromal-epithelial interaction. An increase in TGF-\(\beta\) and IGF signaling will set off the imbalance of this relationship and will lead to cancer development. A continuous input from TGF-\(\beta\) and IGF in the tumor microenvironment will result in cancer progression. Understanding of these events can help prevention, diagnosis, and therapy of prostate cancer.

1. Introduction

Carcinogenesis is a multistep process which begins with initiation followed by promotion and progression [1]. The adjacent stromal cells play an important role in this process [2–4]. The signaling events of transforming growth factor-\(\beta\) (TGF-\(\beta\)) and insulin-like growth factor (IGF-I and IGF-II) in stromal cells occupy a central part in the stromal-epithelial interaction during cancer development and progression [5–9]. In this review, we will propose a hypothesis describing a synergistic role between TGF-\(\beta\) and IGF signaling in stromal-epithelial interaction in prostate cancer.

2. Biology of TGF-\(\beta\) Signaling

TGF-\(\beta\) represents a family of pleiotropic growth factors with diverse functions, such as embryonic development, wound healing, organ development, immunomodulation, and cancer progression [10–12]. There are three known mammalian isoforms of TGF-\(\beta\) (TGF-\(\beta\)1, -\(\beta\)2, and -\(\beta\)3) with significant homology and similarities in function. The biological effect of TGF-\(\beta\) is mediated through type I and type II receptors [13, 14]. The downstream events include both Smad and non-Smad signaling pathways [15–17]. The relative importance and interplay of these pathways of TGF-\(\beta\) signaling are
3. Biology of IGF Signaling

The IGF axis consists of two ligands (IGF-I and IGF-II), two cell surface receptors (IGF-IR and IGF-IIR), 6 binding proteins (IGFBP-1 to 6), and a group of IGFBP degrading enzymes [22–24]. Among IGFBPs, IGFBP-3 is the most abundant in the prostate and is able to bind IGF-I and thus controls the amount of available IGF-I to interact with IGF-IR in target cells. IGF-IR is a tyrosine kinase receptor. Upon engagement with IGF-I or IGF-II, IGF-IR is activated by phosphorylation and activates downstream mitogenic signals, including MAPK and PI3K. IGF-IIR does not have the intracellular kinase domain and its role in cellular proliferation remains unclear [25]. An important aspect of IGF signaling in prostate cancer development and progression is that it is able to activate androgen receptor nuclear translocation in the absence of androgen [26–28]. Epidemiologic and laboratory evidence strongly suggests that elevated IGF-1 levels are associated with increased risk of prostate cancer [5, 25, 29].

4. Stromal-Epithelial Interaction in the Normal Prostate: The Prostatic Ductal System

During embryogenesis, epithelial cells in the ectoderm change into mesenchymal cells, which migrate through the primitive streak and insert themselves between the ectoderm and the endoderm. Some of these mesenchymal cells will engage in the establishment and maintenance of a lifelong relationship with the epithelial cells. The reciprocal relationship between the stroma and epithelia in the urogenital sinus has created a unique microenvironment which directed the urogenital sinus to be destined to the development of the prostate [30].

In the normal prostate, TGF-β is a gate keeper to maintain cellular homeostasis and structural integrity. The cross talk between two cellular components is mainly centered on the TGF-β and IGF signaling. The adult prostate is arranged as individual ductal systems, consisting of the proximal, intermediate, and distal regions [31, 32]. The integrity of these regions is maintained in a homeostatic state through a tightly regulated TGF-β signaling cross talk between the stromal and epithelial compartments [33–35]. The epithelial compartment in the distal region contains proliferative cells; the epithelial cells in the proximal region are undergoing apoptosis. The majority of the epithelial cells in the ductal system are located in the intermediate region and are in a differentiated, proliferative quiescent state [31, 32]. The adjacent stromal compartment consists of fibroblasts and smooth muscle cells. Smooth muscle cells are concentrated in the proximal region as they produce high levels of TGF-β, while the fibroblasts are lined in the distal region and produce little or no TGF-β [32, 34]. This regional differential production of TGF-β is critical, in that TGF-β is a potent inhibitor for proliferation in the adjacent epithelial cells. The maintenance of cellular homeostasis within this ductal system implemented by a regional variation in stromal-epithelial cross talk is mediated by a corresponding regional TGF-β signaling. A disturbance of this delicate balance between the stroma and the epithelia will result in abnormal growth of the prostate, such as benign prostatic hyperplasia and prostate cancer, when the IGF signaling system derived from the stromal cells through a paracrine fashion to play a synergistic role [23, 29].

5. A Biphasic Effect of TGF-β on Normal Prostate Stromal and Epithelial Cells

TGF-β, under normal physiological conditions, is a gate keeper to maintain cellular homeostasis, including the maintenance of the normal integrity of the prostate. A common notion is that TGF-β is inhibitory to cell growth and proliferation in normal cells. This notion needs to be modified. Results of our studies have demonstrated a biphasic effect of TGF-β on both prostatic stromal [36] and epithelial cells [37]. At a low dose (0.1 ng/mL), TGF-β can stimulate cell proliferation through the induction of mitogenic factors [37, 38], while, at a high dose (10 ng/mL), TGF-β inhibits cell proliferation through the induction of CDK inhibitors and inactivation of Erk [36, 37]. The biphasic effect of TGF-β offers a mechanism to maintain cellular homeostasis under normal physiological conditions.

6. The TGF-β Paradox and Differential Effect of TGF-β between Benign and Cancer Cells

It has been known that the effect of TGF-β is different between benign and cancer cells. TGF-β mediates growth inhibition and apoptosis in benign cells but facilitates progression and metastasis in cancer cells [37]. The mechanism for this differential effect of TGF-β remains unclear. Results of our studies have observed a differential effect of TGF-β on Erk activation between benign and cancer cells which have provided a partial answer to this paradox. At low dose of TGF-β (0.1 ng/mL), both benign cells and cancer cells undergo Erk activation and induction of TGF-β production [37]. At high doses (10 ng/mL), TGF-β inhibits Erk activation in benign cells, but, in cancer cells, TGF-β continuously mediates Erk activation and induction of TGF-β production [37, 39]. This differential effect of TGF-β constitutes a critical event in the TGF-β paradox and creates a unique tumor microenvironment that sets off a vicious cycle to promote tumor progression. In the following paragraphs, we will discuss the role of adjacent stromal cells in prostate cancer development, progression, and metastasis.
Fibroblast-to-myofibroblast transdifferentiation is a hallmark of benign prostatic hyperplasia and prostate cancer [40–43]. The presence of myofibroblasts is known to promote proliferation of the adjacent epithelial cells in the prostate [42, 43]. Unlike the normal fibroblasts which do not produce TGF-\(\beta\), CAFs produce large amounts of TGF-\(\beta\), which is the inducing stimulus for growth of the adjacent epithelial cells [43, 44]. Direct stimulation of fibroblasts with TGF-\(\beta\) can induce the transdifferentiation of fibroblasts to myofibroblasts with Erk activation [41], which may also require activation of Smad3 [40]. Myofibroblasts express and secrete proinvasive factors significantly increasing the invasive capacity of tumor cells via paracrine mechanisms. Reactive stroma can also be induced by down regulating TGF-\(\beta\) receptors, which will lead to an increased production of TGF-\(\beta\). This is illustrated by the introduction of a dominant negative type II TGF-\(\beta\) receptor into prostate stromal cells resulting in an increase in the simultaneous expression of vimentin and \(\alpha\)-smooth muscle actin (definition of myofibroblasts) through the activation of the AKT pathway [44]. Conversely, the myofibroblast phenotype can be detected adjacent to established cancer [45]. In the present review, we will use the term cancer-associated fibroblasts (CAFs) in place of reactive stroma or myofibroblasts.

7. Reactive Stroma—Myofibroblasts or Cancer-Associated Fibroblasts (CAFs)

8. Role of the Adjacent Stroma in Prostate Carcinogenesis

Under normal physiological conditions, the homeostasis of the normal prostate is carefully maintained by the well-orchestrated stromal-epithelial cross talk through a tightly regulated TGF-\(\beta\) signaling in a paracrine fashion [32]. An imbalance in TGF-\(\beta\) signaling within this normal stromal-epithelial interaction will result in abnormal growth of the prostate. During prostatic carcinogenesis in rats and humans, the adjacent stroma undergoes progressive loss in smooth muscle with the appearance of CAFs [43, 46, 47]. Perhaps the best example is the report by Bhowmick et al. in 2004 [48] in which they introduced a dominant negative type II TGF-\(\beta\) receptor into prostate stromal cells resulting in the loss of TGF-\(\beta\) responsiveness in these stromal cells, which assumed a myofibroblast phenotype. These genetically altered fibroblasts also produce elevated TGF-\(\beta\) [49]. In retrospect, it becomes apparent that these CAF cells not only produced an increased level of TGF-\(\beta\), but also produced an increased level of IGF-I [50, 51]. We hypothesize that under the combined influence of elevated TGF-\(\beta\) and IGF-I, along with the input from androgen/estrogen signaling, the adjacent epithelial cells eventually developed into prostate cancer. This assumption implies that an increased TGF-\(\beta\) and IGF-I signaling in the adjacent stromal cells can lead to the development of prostate cancer [44]. Indeed, it has been shown that myofibroblasts contained a reduced level of TGF-\(\beta\) receptors when compared to that in the normal fibroblasts [52]. Further, it is interesting that the CAF cells with aberrant TGF-\(\beta\) signaling events can also interact with the neighboring normal stromal cells to jointly impact prostate carcinogenesis [44]. In conclusion, an imbalance in TGF-\(\beta\) signaling by a reduction in TGF-\(\beta\) sensitivity and an increased production of TGF-\(\beta\) coupled with an increased IGF-I signaling in the CAF cells is able to bring about malignant transformation in the adjacent epithelial cells in the prostate [29, 48, 49].

We postulate that an intricate interaction between TGF-\(\beta\) and IGF-I signaling in prostate CAF cells has created a unique microenvironment which is conducive for cancer development and progression in the adjacent epithelial cells. Prostate CAF cells are able to produce IGF-I in response to TGF-\(\beta\) [50, 51]. Likewise, CAF cells are able to produce TGF-\(\beta\)I in response to IGF-I [53]. Such an interaction has created a positive feedback loop to stimulate the adjacent epithelial cells to undergo proliferation and carcinogenesis [29].

9. Role of the Adjacent Stroma in Tumor Progression

In prostate cancer, both the cancer cells and the adjacent CAFs will mediate oncogenic signals to fuel the cancer progression and metastasis [45, 46, 54]. Again, an aberrant TGF-\(\beta\) signaling in both the CAF and the adjacent epithelial compartment sets off a vicious cycle for progression and metastasis [55–57]. Many paracrine signals promote prostate cancer cell adhesion in the bone matrix. Fibroblast-to-myofibroblast transdifferentiation can lead to many activities of TGF-\(\beta\) mediated events in cancer. These events include changes in cytokine balances, EMC proteins, proteases, and IGF-I production, resulting in cancer invasion and ectopic survival, angiogenesis, and evasion of host immune surveillance program [55, 57–59]. In addition to contributing to cytokines, modified ECM, proteases, and protease inhibitors, myofibroblasts themselves are able to invade into cancer cell compartment [60]. In a recent paper [61], we observed an increased expression of TGF-\(\beta\)I, IGF-I, and IGF-II in the stromal cells adjacent to prostate cancer. These levels correlated with the Gleason score of the disease, suggesting that expression of TGF-\(\beta\)I, IGF-I, and IGF-II is associated with cancer progression (Figure 1). In fact, genetic signatures in the stroma can be used to detect the presence of malignancy in adjacent epithelial cells [61].

10. Androgen Receptor (AR) and Androgen Action

AR in the stroma is known to play a role in normal and malignant prostate [30, 46]. AR is detected in both epithelial and stromal cells, in cancer, as well as in benign prostate [62]. Both TGF-\(\beta\) and IGF-I can interact with AR function in the prostate. IGF signaling can result in AR translocation to the nucleus in the absence of androgen [26–28]. Androgen can also upregulate IGF-I production from prostate stromal cells [63]. Results of many studies indicated that AR signaling can negatively regulate TGF-\(\beta\) signaling through the negative AR response element [64, 65], while TGF-\(\beta\) signaling represses AR signaling through Smad3 [66]. However, corroboration
can also upregulate IGF-IR through a nongenotrophic pathway in prostate cancer cells [73]. A recent report indicated that expression of ERα in CAF would suppress prostate cancer invasion [74]. Since cancer cell invasion is mediated by TGF-β signaling, this observation supports the notion that there is a negative interaction between ER-α and TGF-β signaling [75]. A unique property of estrogen is its ability to be metabolized to 2-catechol estrogen, which may react with DNA to form depurinated adducts [76, 77]. These DNA adducts will lead to cancer initiation. This is also consistent with the report that high circulating estrogen is associated with increased incidence of prostate cancer [78].

12. Combination of Androgen and Estrogen in Prostate Carcinogenesis

The best example of prostate cancer generation is treating Noble rats with a combination of androgen and estrogen and tumors were developed in the dorsal lobe of the prostate [29, 79, 80]. Prostate cancer can also be generated by a combination of stromal cells with basal prostatic epithelial cells with both estrogen and testosterone [81], while testosterone alone would not induce prostate cancer. A classical study by [82] has illustrated the significance of a combination of androgen and estrogen affecting the stromal cells to promote prostate cancer development. In untreated mouse hosts, UGM + BPH-1 recombinants produced solid branched epithelial cords and ductal structures exhibiting benign growth. In T + E2-treated hosts, UGM + BPH-1 recombinants formed invasive carcinomas. BPH-1 cells lack androgen and estrogen receptors, whereas rat UGM expresses both of these receptors. IGF-I signaling is responsible for carcinogenesis as elicited by T + E2 in the stromal microenvironment [29]. DNA adducts are observed in Noble rats [83]. Based on this review, we postulate that the effect of androgen/estrogen causes DNA damage and is the initiation step for prostate carcinogenesis, while the impact of TGF-β and IGF signaling is the promotion step leading to cancer development and progression.

13. Conclusions: Targeting the Stromal Cells for Cancer Diagnosis, Prevention, and Therapy

Based on the above discussion, we understand that contributions from the adjacent stromal cells can control tumor development and progression. As depicted in Figure 2, we propose the hypothesis that an imbalance in signaling between TGF-β and IGF in the stromal cells adjacent to prostate epithelial cells is responsible for the carcinogenesis process which perpetuates this imbalance in a vicious cycle to further promote cancer progression. Initially, the carcinogenesis initiation step is thought to be the result of androgen/estrogen action. Subsequently, the carcinogenesis promotion step is thought to be triggered by the TGF-β/IGF signaling. A downregulation of TGF-β receptors in the stromal cells will result in an increase in TGF-β expression. An increased level of TGF-β in the microenvironment will induce the expression of IGF-1/IGF-II and IGFBP-3. IGFBP-3 will regulate the bioavailability of

11. Estrogen Receptors (ER) and Estrogen Action

17β-Estradiol is a natural estrogen produced in both males and females. It mediates its action through interaction with estrogen receptor (ER). There are three types of estrogen receptors, ERα, ERβ, and GPR30 [70]. ERα and GPR30 promote proliferation, whereas ERβ has proapoptotic and prodifferentiating functions [70, 71]. Prostate stromal cells contain mainly ERα and GPR30 [69]. E2 stimulates production of TGF-β in prostate stromal cells through ERα [72]. E2
IGF-I/IGF-II. However, IGFBPs can be degraded by PSA and MMPs [23, 50, 84], as a result of TGF-β and IGF are tightly regulated keeping the epithelial cells under a homeostatic balance. A reduction in TBRs in the stromal cells will result in an increase in IGF production, which has a proliferative effect on the prostate epithelial cells which have undergone a cancer initiation process as a result of T + E2. TGF-β and IGF in the stromal cells adjacent to prostate epithelial cells will perpetuate a vicious cycle to promote cancer progression.

**Conflict of Interests**

M. McClelland and D. Mercola are cofounders of Proveri Inc., which is engaged in translational development of aspects of the subject matter. The other authors disclosed no potential conflict of interests.

**Acknowledgments**

Studies in this report are supported by research Grants from the National Cancer Institute (U01 CA152738 EDRN, U01 CA114810 SPECS, P50 CA90386 SPORE) and the Department of Defense (W81XWH-09-1-0311 and W81XWH-08-1-0720).

**References**

[1] E. R. Fearon and B. Vogelstein, “A genetic model for colorectal tumorigenesis,” Cell, vol. 61, no. 5, pp. 759–767, 1990.

[2] L. W. K. Chung, W.-C. Huang, S.-Y. Sung et al., “Stromal-epithelial interaction in prostate cancer progression,” Clinical Genitourinary Cancer, vol. 5, no. 2, pp. 162–170, 2006.

[3] Y.-N. Niu and S.-J. Xia, “Stroma-epithelium crosstalk in prostate cancer,” Asian Journal of Andrology, vol. 11, no. 1, pp. 28–35, 2009.

[4] A. Y. Liu, L. E. Pascal, R. Z. Vêncio, and E. F. Vêncio, “Stromal-epithelial interactions in early neoplasia,” Cancer Biomarkers, vol. 9, no. 1–6, pp. 141–155, 2011.

[5] M. Pollak, W. Beamer, and J.-C. Zhang, “Insulin-like growth factors and prostate cancer,” Cancer and Metastasis Reviews, vol. 17, no. 4, pp. 383–390, 1999.

[6] C. Gennigens, C. Menetrier-Caux, and J. P. Droz, “Insulin-Like Growth Factor (IGF) family and prostate cancer,” Critical Reviews in Oncology/Hematology, vol. 58, no. 2, pp. 124–145, 2006.

[7] B. Berie and H. L. Moses, “TGF-β and cancer,” Cytokine and Growth Factor Reviews, vol. 17, no. 1-2, pp. 29–40, 2006.

[8] D. G. Stover, B. Berie, and H. L. Moses, “A delicate balance: TGF-β and the tumor microenvironment,” Journal of Cellular Biochemistry, vol. 101, no. 4, pp. 851–861, 2007.

[9] M. A. Kiskowski, R. S. Jackson II, J. Banerjee et al., “Role for stromal heterogeneity in prostate tumorigenesis,” Cancer Research, vol. 71, no. 10, pp. 3459–3470, 2011.

[10] J. Massague, “The transforming growth factor-β family,” Annual Review of Cell Biology, vol. 6, pp. 597–641, 1990.

[11] J. Massagué, “How Cells read TGF-beta signals,” Nature Reviews Molecular Cell Biology, vol. 1, pp. 169–178, 2000.

[12] R. Derynck, R. J. Akhurst, and A. Balmain, “TGF-beta signaling in tumor suppression and cancer progression,” Nature Genetics, vol. 29, pp. 117–129, 2001.

[13] J. Massague, S. Cheifetz, M. Laiho, D. A. Ralph, F. M. B. Weis, and A. Zentella, “Transforming growth factor-β,” Cancer Surveys, vol. 12, pp. 81–103, 1992.

[14] R. Derynck and X.-H. Feng, “TGF-β receptor signaling,” Biochimica et Biophysica Acta, vol. 1333, no. 2, pp. F105–F150, 1997.

[15] J. S. Kang, C. Liu, and R. Derynck, “New regulatory mechanisms of TGF-β receptor function,” Trends in Cell Biology, vol. 19, no. 8, pp. 385–394, 2009.

[16] M. Hong, M. C. Wilkes, S. G. Penheter, S. K. Gupta, M. Edens, and E. B. Leof, “Non-Smad transforming growth factor-β signaling regulated by focal adhesion kinase binding the p85 subunit of phosphatidylinositol 3-kinase,” Journal of Biological Chemistry, vol. 286, no. 20, pp. 17841–17850, 2011.

[17] Y. Mu, S. K. Gudey, and M. Landström, “Non-Smad signaling pathways,” Cell and Tissue Research, vol. 347, no. 1, pp. 11–20, 2012.

[18] K. Miyazono, “Transforming growth factor-β signaling in epithelial-mesenchymal transition and progression of cancer,” Proceedings of the Japan Academy B, vol. 85, no. 8, pp. 314–323, 2009.

[19] L. Lu, J. Wang, F. Zhang et al., “Role of SMAD and non-SMAD signals in the development of Th17 and regulatory T cells,” Molecular Immunology, vol. 184, no. 8, pp. 4295–4306, 2010.

[20] K. Aomatsu, T. Arao, K. Sugioka et al., “TGF-β induces sustained upregulation of SNAI1 and SNAI2 through smad and non-smad pathways in a human corneal epithelial cell line,” Investigative Ophthalmology and Visual Science, vol. 52, no. 5, pp. 2437–2443, 2011.

[21] S. Lamouille and R. Derynck, “Emergence of the phosphoinositide 3-kinase-akt- mammalian target of rapamycin axis in transforming growth factor-β-induced epithelial- mesenchymal transition,” Cells Tissues Organs, vol. 193, no. 1-2, pp. 8–22, 2010.
[22] D. M. Peehl, P. Cohen, and R. G. Rosenfeld, “The insulin-like growth factor system in the prostate,” *World Journal of Urology*, vol. 13, no. 5, pp. 306–311, 1995.

[23] P. Cohen, D. M. Peehl, B. Baker, F. Liu, R. L. Hintz, and R. G. Rosenfeld, “Insulin-like growth factor axis abnormalities in prostatic stromal cells from patients with benign prostatic hyperplasia,” *Journal of Clinical Endocrinology and Metabolism*, vol. 79, no. 5, pp. 1410–1415, 1994.

[24] S. Kojima, M. Inahara, H. Suzuki, T. Ichikawa, and Y. Furuya, “Implications of insulin-like growth factor-I for prostate cancer therapies,” *International Journal of Urology*, vol. 16, no. 2, pp. 161–167, 2009.

[25] K. M. Biernacka, C. M. Perks, and J. M. P. Holly, “Role of the IGF axis in prostate cancer progression,” *Minerva Endocrinologica*, vol. 37, no. 2, pp. 173–185, 2012.

[26] Z. Culig, A. Hobisch, M. V. Cronauer et al., “Activation of the androgen receptor by polypeptide growth factors and cellular regulators,” *World Journal of Urology*, vol. 13, no. 5, pp. 285–289, 1995.

[27] Z. Culig, A. Hobisch, M. V. Cronauer et al., “Androgen receptor activation in prostatic tumour cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor,” *Cancer Research*, vol. 54, no. 20, pp. 5474–5478, 1994.

[28] A. Sayeed, N. Alam, M. Trerotola, and L. R. Languino, “Insulin-like growth factor stimulation of androgen receptor activity requires β1 integrins,” *Journal of Cellular Physiology*, vol. 227, no. 2, pp. 751–758, 2012.

[29] Y. Z. Wang and Y. C. Wong, “Sex hormone-induced prostatic carcinogenesis in the Noble rat: the role of insulin-like growth factor-1 (IGF-I) and vascular endothelial growth factor (VEGF) in the development of prostate cancer,” *Prostate*, vol. 35, pp. 165–177, 1998.

[30] G. R. Cunha, “Role of mesenchymal-epithelial interactions in normal and abnormal development of the mammary gland and prostate,” *Cancer*, vol. 74, no. 3, pp. 1030–1044, 1994.

[31] C. Lee, J. A. Sensibar, S. M. Dudek, and R. A. Hiipakka, “Prostatic ductal system in rats: regional variation in morphological and functional activities,” *Biology of Reproduction*, vol. 43, no. 6, pp. 1079–1086, 1990.

[32] C. Lee, “Biology of the prostatic ductal system,” in *Prostate: Clinical and Basic Aspects*, R. Nez, Ed., pp. 53–71, CRC Press, Boca Raton, Fla, USA, 1997.

[33] J. A. Sensibar, M. D. Griswold, S. R. Sylvester et al., “Prostatic ductal system in rats: regional variation in localization of an androgen-repressed gene product, sulfated glycoprotein-2,” *Endocrinology*, vol. 128, no. 4, pp. 2091–2102, 1994.

[34] J. A. Nemeth and C. Lee, “The prostatic ductal system in rats: regional variation in stromal organization,” *Prostate*, vol. 28, pp. 124–128, 1996.

[35] K. Y. Ilio, J. A. Nemeth, J. A. Sensibar, S. Lang, and C. Lee, “The prostatic ductal system in rats: changes in regional distribution of ECM proteins during castration-induced regression,” *Prostate*, vol. 43, pp. 3–10, 2000.

[36] W. Zhou, I. Park, M. Pins et al., “Dual regulation of proliferation and growth arrest in prostatic stromal cells by transforming growth factor β1,” *Endocrinology*, vol. 144, no. 10, pp. 4280–4284, 2003.

[37] N. Yu, J. M. Kozlowski, I. I. Park et al., “Overexpression of transforming growth factor β1 in malignant prostate cells is partly caused by a runaway of TGF-β1 Auto-induction mediated through a defective recruitment of protein phosphatase 2A by TGF-β type I receptor,” *Urology*, vol. 76, no. 6, pp. 1519.e8–1519.e13, 2010.

[38] Y. Hirarsawa, T. Sakai, M. Ito, H. Yoshimura, Y. Feng, and T. Nagamatsu, “Advanced-glycation-end-product-cholesterol-aggregated-protein accelerates the proliferation of mesangial cells mediated by transforming-growth-factor-β1 receptors and the ERK-MAPK pathway,” *European Journal of Pharmacology*, vol. 672, no. 1–3, pp. 159–168, 2011.

[39] Q. Zhang, L. Chen, B. T. Helfand et al., “Transforming Growth Factor-α-induced DNA methyltransferase contributes to aggressive prostate cancer phenotypes and predicts biochemical recurrence after radical prostatectomy,” *PloS ONE*, vol. 6, Article ID e25168, 2011.

[40] L. Gu, Y.-J. Zhu, X. Yang, Z.-J. Guo, W.-B. Xu, and X.-L. Tian, “Effect of TGF-β/Smad signaling pathway on lung myofibroblast differentiation,” *Acta Pharmacologica Sinica*, vol. 28, no. 3, pp. 382–391, 2007.

[41] F. Caraci, E. Gili, M. Calafiori et al., “TGF-β targets the GSK-3β/β-catenin pathway via ERK activation in the transition of human lung fibroblasts into myofibroblasts,” *Pharmacological Research*, vol. 57, no. 4, pp. 274–282, 2008.

[42] A. Shaw, J. Gipp, and W. Bushman, “The Sonic Hedgehog pathway stimulates prostate tumor growth by paracrine signaling and recapitulates embryonic gene expression in tumor myofibroblasts,” *Oncogene*, vol. 28, no. 50, pp. 4480–4490, 2009.

[43] I. G. Schauer and D. R. Rowley, “The functional role of reactive stroma in benign prostatic hyperplasia,” *Differentialiation*, vol. 82, no. 4-5, pp. 200–210, 2011.

[44] O. E. Franco, M. Jiang, D. W. Strand et al., “Altered TGF-β signaling in a subpopulation of human stromal cells promotes prostatic carcinogenesis,” *Cancer Research*, vol. 71, no. 4, pp. 1272–1281, 2011.

[45] O. de Wever, P. Demetter, M. Mareel, and M. Bracke, “Stromal myofibroblasts are drivers of invasive cancer growth,” *International Journal of Cancer*, vol. 123, no. 10, pp. 2229–2238, 2008.

[46] L. W. K. Chung, “The role of stromal-epithelial interaction in normal and malignant growth,” *Cancer Surveys*, vol. 23, pp. 33–42, 1995.

[47] D. R. Rowley, “What might a stromal response mean to prostate cancer progression?” *Cancer and Metastasis Reviews*, vol. 17, no. 4, pp. 411–419, 1999.

[48] N. A. Bhowmick, A. Chyttil, D. Pletih et al., “TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia,” *Science*, vol. 303, no. 5659, pp. 848–851, 2004.

[49] M. Ao, O. E. Franco, D. Park, D. Raman, K. Williams, and S. W. Hayward, “Cross-talk between paracrine-acting cytokine and chemokine pathways promotes malignancy in benign human prostatic epithelium,” *Cancer Research*, vol. 67, no. 9, pp. 4244–4253, 2007.

[50] M. Kawada, H. Inoue, M. Arakawa, and D. Ikeda, “Transforming growth factor-β1 modulates tumor-stromal cell interactions of prostate cancer through insulin-like growth factor-I,” *Anticancer Research*, vol. 28, no. 2, pp. 721–730, 2008.

[51] M. Kawada, H. Inoue, I. Usami, and D. Ikeda, “Pthoxazolin A inhibits prostate cancer growth by modulating tumor-stromal cell interactions,” *Cancer Science*, vol. 100, no. 1, pp. 150–157, 2009.

[52] S. Dooley, B. Delvoux, B. Lahme, K. Mangasser-Stephan, and A. M. Gressner, “Modulation of transforming growth factor β response and signaling during transdifferentiation of rat hepatic stellate cells to myofibroblasts,” *Hepatology*, vol. 31, no. 5, pp. 1094–1106, 2000.
J. E. Chipuk, S. C. Cornelius, N. J. Pultz et al., “The androgen receptor represses transforming growth factor-β signaling through interaction with Smad3,” *Journal of Biological Chemistry*, vol. 277, no. 2, pp. 1240–1248, 2002.

W. Qi, S. Gao, J. Chu, L. Zhou, and Z. Wang, “Negative androgen-response elements mediate androgen-dependent transcriptional inhibition of TGF-β1 and CDK2 promoters in the prostate gland,” *Journal of Andrology*, vol. 33, no. 1, pp. 27–36, 2012.

S. A. Hayes, M. Zarnegar, M. Sharma et al., “SMAD3 represses androgen receptor-mediated transcription,” *Cancer Research*, vol. 61, no. 5, pp. 2112–2118, 2001.

H.-Y. Kang, H.-K. Lin, Y.-C. Hu, S. Yeh, K.-E. Huang, and C. Chang, “From transforming growth factor-β signaling to androgen action: identification of Smad3 as an androgen receptor coregulator in prostate cancer cells,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 98, no. 6, pp. 3018–3023, 2001.

M.-L. Zhu, J. V. Partin, E. M. Bruckheimer, S. E. Strup, and N. Kyripanou, “TGF-β signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells,” *Prostate*, vol. 68, no. 3, pp. 287–295, 2008.

H.-Y. Kang, K.-E. Huang, S. Y. Chang, W.-L. Ma, W.-J. Lin, and C. Chang, “Differential modulation of androgen receptor-mediated transactivation by Smad3 and tumor suppressor Smad4,” *Journal of Biological Chemistry*, vol. 277, no. 46, pp. 43749–43756, 2002.

I. I. Park, Q. Zhang, V. Liu, J. M. Kozlowski, J. Zhang, and C. Lee, “1β-Estradiol at low concentrations acts through distinct pathways in normal versus benign prostatic hyperplasia-derived prostate stromal cells,” *Endocrinology*, vol. 150, no. 10, pp. 4594–4605, 2009.

A. Morani, M. Warner, and J.-A. Gustafsson, “Biological functions and clinical implications of oestrogen receptors α and β in epithelial tissues,” *Journal of Internal Medicine*, vol. 264, no. 2, pp. 128–142, 2008.

G. Pandini, M. Genua, F. Frasca, S. Squarrito, R. Vigneri, and A. Belfiore, “17β-estradiol up-regulates the insulin-like growth factor receptor through a nongenotropic pathway in prostate cancer cells,” *Cancer Research*, vol. 67, no. 18, pp. 8932–8941, 2007.

L. Yu, C.-Y. Wang, J. Shi et al., “Estrogens promote invasion of prostate cancer cells in a paracrine manner through up-regulation of matrix metalloproteinase 2 in prostate stromal cells,” *Endocrinology*, vol. 152, no. 3, pp. 773–781, 2011.

S. Slavin, C. R. Yeh, J. Da et al., “Estrogen receptor α in cancer-associated fibroblasts suppresses prostate cancer invasion via modulation of thrombospondin 2 and matrix metalloproteinase 3,” *Carcinogenesis*, 2014.

A. Dhasarathy, D. Phadke, D. Maj, R. R. Shah, and P. A. Wade, “The transcription factors snail and slug activate the transforming growth factor-beta signaling pathway in breast cancer,” *PLoS ONE*, vol. 6, no. 10, Article ID e26514, 2011.

E. L. Cavaleri and E. G. Rogan, “A unified mechanism in the initiation of cancer,” *Cellular and Molecular Life Sciences*, vol. 59, no. 4, pp. 665–681, 2002.

E. L. Cavaleri and E. G. Rogan, “Unbalanced metabolism of endogenous estrogens in the etiology and prevention of human cancer,” *Journal of Steroid Biochemistry and Molecular Biology*, vol. 125, no. 3–5, pp. 169–180, 2011.

Z. Y. Abd Elmageed, K. Moroz, S. K. Srivastav et al., “High circulating estrogens and selective expression of ERβ in prostate tumors of Americans: implications for racial disparity of prostate cancer,” *Carcinogenesis*, vol. 34, no. 9, pp. 2017–2023, 2013.

R. L. Noble, “Production of Nb rat carcinoma of the dorsal prostate and response of estrogen-dependent transplants to sex hormones and tamoxifen,” *Cancer Research*, vol. 40, no. 10, pp. 3547–3550, 1980.

S.-M. Ho and D. Roy, “Sex hormone-induced nuclear DNA damage and lipid peroxidation in the dorsolateral prostates of Noble rats,” *Cancer Letters*, vol. 84, no. 2, pp. 155–162, 1994.

R. A. Taylor, R. Toivanen, M. Frydenberg et al., “Human epithelial basal cells are cells of origin of prostate cancer, independent of CD133 status,” *Stem Cells*, vol. 30, no. 6, pp. 1087–1096, 2012.

G. R. Cunha, S. W. Hayward, Y. Z. Wang, and W. A. Ricke, “Role of the stromal microenvironment in carcinogenesis of the prostate,” *International Journal of Cancer*, vol. 107, no. 1, pp. 1–10, 2003.
[83] E. L. Cavalieri, P. Devanesan, M. C. Bosland, A. F. Badawi, and E. G. Rogan, “Catechol estrogen metabolites and conjugates in different regions of the prostate of Noble rats treated with 4-hydroxyestradiol: implications for estrogen-induced initiation of prostate cancer,” Carcinogenesis, vol. 23, no. 2, pp. 329–333, 2002.

[84] P. Cohen, D. M. Peehl, H. C. B. Craves, and R. C. Rosenfeld, “Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease,” Journal of Endocrinology, vol. 142, no. 3, pp. 407–415, 1994.

[85] S. Lonning, J. Mannick, and J. M. McPherson, “Antibody targeting of TGF-β in cancer patients,” Current Pharmaceutical Biotechnology, vol. 12, no. 12, pp. 2176–2189, 2011.

[86] S.-Y. Sung and L. W. K. Chung, “Prostate tumor-stroma interaction: molecular mechanisms and opportunities for therapeutic targeting,” Differentiation, vol. 70, no. 9-10, pp. 506–521, 2002.

[87] F. I. Arnaldez and L. J. Helman, “Targeting the insulin growth factor receptor 1,” Hematology/Oncology Clinics of North America, vol. 26, no. 3, pp. 527–542, 2012.
